These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2014-000667-40||A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension||2017-06-22||bad-data|
|Ongoing||2014-003042-27||An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension||not-yet-due|
|Listed as ongoing, but also has a completion date and reported results||2015-001942-28||A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative C...||2018-02-15||bad-data|
|Listed as ongoing, but also has a completion date||2015-002109-12||An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis||2018-10-11||bad-data|
|Not reported||2016-003797-40||A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations||2017-10-02||due-trials|
|Ongoing||2018-001187-33||A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients||not-yet-due|
|Ongoing||2018-001189-40||A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION||not-yet-due|